Newsroom

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with aPAP. ATS 2025 Posters Poster Ti...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Krispy Kreme, Inc. (“Krispy Kreme” or the “Company”) (NASDAQ: DNUT) securities between February 25, 2025 and May 7, 2025, inclusive (the “Class Period”). Krispy Kreme investors have until July 15, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN KRISPY KREME, INC. (DNUT), CONTACT THE LAW OFFICES OF HOWARD G. S...

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Elevance business and prospects, resulting in its stock trading at inflated prices....

BERKELEY, Calif.--(BUSINESS WIRE)--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today reported results from multi-site clinical experiences with IMVARIA’s diagnostic referral service, where pulmonologists send cases for AI-supported diagnostic evaluation of suspected Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF). Built by medical doctors with software engineering expertise, Fibresolve is the first ever FDA-authorized AI adjuncti...

MCLEAN, Va.--(BUSINESS WIRE)--Capital One Financial Corporation (NYSE: COF) today announced that it has completed its acquisition of Discover Financial Services. “This deal brings together two innovative, mission-driven companies that together are poised to deliver breakthrough products and experiences to consumers, businesses, and merchants,” said Richard D. Fairbank, Founder and CEO of Capital One. “I am particularly grateful for the leadership and partnership of Discover’s Board of Directors...

纽约--(BUSINESS WIRE)--(美国商业资讯)-- 全球投资者权益律师事务所Rosen Law Firm提醒投资者，一名股东代表在2023年3月17日至2024年11月17日期间购买Sana Biotechnology, Inc.（NASDAQ：SANA）证券的投资者提起集体诉讼。Sana是一家生物技术公司。 如需了解更多信息，请提交表格，向Phillip Kim律师发送电子邮件或致电866-767-3653联系我们。 指控内容：Rosen Law Firm正在调查有关Sana Biotechnology, Inc. （NASDAQ: SANA）在业务运营方面误导投资者的指控。 起诉书称，在集体诉讼期间，被告作出了虚假和/或误导性陈述和/或未能披露以下事实： (1) Sana面临资金不足，无法维持当前运营和推进一个或多个候选产品的的重大风险；(2) SC291（肿瘤学领域）、SC379和SG299的实际前景不如被告方此前向投资者所宣称的那样乐观；(3) 为了保留现金和推进更有前景的候选产品，Sana可能会减少对SC291（肿瘤学领域）、SC379和SG299的资助和/或停止...

ST. LOUIS--(BUSINESS WIRE)--U-Haul® has made 24 Company stores across three states available to help storm victims with 30 days of free self-storage and U-Box® container usage after a powerful weather system spawned a number of deadly tornadoes on Friday. The tornadoes tore through homes — and in some cases communities — while being responsible for more than 20 casualties, according to news reports. Many families remain without power and face a long rebuilding process. While St. Louis and other...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024. Sana is a biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Sana Biotechnology, In...

MALVERN, Pennsylvania, USA, und TOKIO--(BUSINESS WIRE)--Wie Fujirebio heute mitteilte, hat die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) die 510(k)-Zulassung für den Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-vitro-Diagnosetest (IVD) erteilt. Der Test ermöglicht die Beurteilung der Amyloidpathologie bei Patienten, die auf Alzheimer-Krankheit und andere Ursachen eines kognitiven Verfalls untersucht werden, und wurde von der FDA als „Breakthrough Device De...

MALVERN, Pa., & TOKYO--(BUSINESS WIRE)--Fujirebio heeft vandaag aangekondigd dat de Amerikaanse Food and Drug Administration (FDA) 510(k) goedkeuring heeft verleend voor de Lumipulse ® G pTau 217/β-Amyloid in-vitro diagnostische (IVD) test met plasmaverhouding van 1-42 van het bedrijf voor de beoordeling van amyloïde pathologie bij patiënten die worden onderzocht op de ziekte van Alzheimer en andere oorzaken van cognitieve achteruitgang. Deze bekendmaking is officieel geldend in de originele br...